ACA Stock Recent News

Arcosa, Inc. (NYSE:ACA ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Erin Drabek - Director of Investor Relations Antonio Carrillo - President and Chief Executive Officer Gail Peck - Chief Financial Officer Conference Call Participants Julio Romero - Sidoti & Company. Brent Thielman - D.A.

Arcosa (ACA) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.73 per share a year ago.

DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa,” the “Company,” “We,” or “Our”), a provider of infrastructure-related products and solutions, today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights   Three Months Ended March 31,   2025   2024   % Change               ($ in millions, except per share amounts)     Revenues $ 632.0     $ 598.6     6 % Revenues, excluding the impact of divested business(1) $ 632.0     $ 562.5     12 % Net income.

ARCB, ACA and BAND have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2025.

The healthcare company also struck a deal with Novo Nordisk to sell Wegovy at a reduced price for cash-paying customers through its pharmacies.

DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced that it will release results for the first quarter ended March 31, 2025 after markets close on Tuesday, May 6, 2025. The Company will host an earnings call to discuss the results at 8:30 a.m. Eastern Time on Wednesday, May 7, 2025. The call can be accessed as follows: Webcast and slide presentation: https://ir.arcosa.com   The slides will be.

AAL, ACA and BLKB have been added to the Zacks Rank #5 (Strong Sell) List on April 15, 2025.

Investors need to pay close attention to Arcosa (ACA) stock based on the movements in the options market lately.

ASTS, AMPY and ACA have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2025.

ACA's topline grew 14.4% YoY in Q4 2024, driven by strong pricing and recent acquisitions, despite a 14% decline in Transportation Products revenue. Expect continued growth in 2025, fueled by strong infrastructure demand, significant backlogs, and contributions from recent acquisitions like Stavola. ACA is optimizing its portfolio through strategic acquisitions and divestitures, aiming to reduce net leverage from 2.9x to its long-term target of 2-2.5x.